Drug
Cnv1014802
Cnv1014802: highest development phase Phase 2, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| CNV1014802 NCT01540630 | Phase 2 | Trigeminal Neuralgia |
Latest
No recent events.
Follow Cnv1014802 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.